Valeranone is a sesquiterpene ketone associated with valerian- and spikenard-related roots and rhizomes rather than with mainstream citrus or mint aroma chemistry. Public evidence is usable but thin: identity data are straightforward, old animal pharmacology papers describe weak sedative, tranquilizing, anti-ulcer, and hypotensive effects, and local oil literature confirms valeranone as a recurring valerian-root marker. That makes valeranone best handled as a chemistry-first archive entry with explicitly historical preclinical evidence and major gaps around modern human safety and efficacy data.
Chemical identity and composition
PubChem identifies valeranone as C15H26O with InChIKey HDVXJTYHXDVWQO-NWANDNLSSA-N and synonym overlap that includes yatamanson. In local archive context it is a notable valerian-root constituent, with the stored multi-country Valeriana officinalis paper reporting 0.5-9.4% across roots from different origins. The literature also ties the molecule to Nardostachys jatamansi pharmacognosy, where the older pharmacology papers often use the yatamanson or jatamansone naming tradition.
Aroma and practical use
- Use the recorded woody, earthy, balsamic, rooty, musky descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1978 animal pharmacology paper reported sedative, tranquilizing, anticonvulsive, anti-ulcer, and weak hypotensive activity for isolated valeranone from Nardostachys jatamansi, but overall potency was lower than standard comparator substances.
The abstract also reports an oral LD50 above 3160 mg/kg in rats and mice, suggesting relatively low acute oral toxicity in that historical dataset.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 1968 clinical-trial record exists for jatamansone/valeranone in hyperkinetic behavior disorders, but no abstract was publicly accessible in this pass, so it is logged only as a literature lead rather than outcome evidence.
The PubMed record confirms publication existence but not interpretable efficacy details from the currently accessible metadata alone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The historical isolated-compound abstract reports an oral LD50 greater than 3160 mg/kg in rats and mice, which suggests low acute oral toxicity in that older animal dataset.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
No modern constituent-specific IFRA restriction, dermal maximum, reproductive toxicology review, or human tolerability study was verified for isolated valeranone in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible pharmacology is old and preclinical, archive copy should avoid presenting valeranone as a proven sleep, anxiety, blood-pressure, or gastrointestinal treatment agent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
sedative-tranquilizing type effects in animal pharmacology models
The 1978 Europe PMC abstract reports prolongation of barbiturate hypnosis, impaired rotarod performance, anticonvulsive effects in electric-shock testing, and potentiation of reserpine-induced temperature lowering.
This experimental finding does not establish benefit, dose or safety in people using this blend.
anti-ulcer effects observed in older pharmacological models
The same historical study reported anti-ulcer activity in three pharmacological models, but the accessible abstract does not establish a modern molecular target.
This experimental finding does not establish benefit, dose or safety in people using this blend.
no modern human-validated target mechanism verified
This pass did not verify a modern receptor-level or human-validated mechanism specific to isolated valeranone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Modern isolated-human evidence for valeranone was not verified; the accessible literature is dominated by older animal pharmacology and composition reports.
- This pass did not verify a contemporary constituent-specific safety assessment comparable to RIFM or CIR for valeranone.
- Valeranone naming overlaps with yatamanson and jatamansone in older literature, so source mapping sometimes depends on synonym interpretation.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.